CTS Corporation Announces Appointment of Kimberly Banks MacKay to its Board of Directors

CTS Corporation, a prominent global designer and manufacturer of custom engineered solutions, has announced the appointment of Kimberly Banks MacKay to its Board of Directors, effective November 5, 2025. In addition to her board role, Ms. MacKay will serve on both the Nominating, Governance and Sustainability Committee, and the Technology and Transactions Committee. With an impressive career spanning over 30 years, she brings extensive expertise from her current position as Senior Vice President, General Counsel, and Corporate Secretary at West Pharmaceutical Services, Inc.

Ms. MacKay is also actively involved in governance roles beyond her corporate duties; she serves on the Board of the Community Foundation of New Jersey and participates in the Compliance, Audit, and Risk Committee for BAYADA Home Health Care. Her vast experience in managing multinational companies and her focus on key end markets position her as a valuable addition to CTS's Board.

Kieran O’Sullivan, Chairman, President, and CEO of CTS, expressed enthusiasm about Ms. MacKay's appointment, noting that her deep experience in the healthcare sector and her leadership in global business will contribute significantly to the company’s ongoing mission. He emphasized the importance of diversity and expertise on the board as CTS continues to pursue growth, enhance end-market diversification, and develop innovative products that “Sense, Connect, and Move.”

CTS Corporation, traded on the NYSE under the ticker CTS, manufactures a range of products, including sensors, actuators, and electronic components, serving various markets such as aerospace, defense, industrial, medical, and transportation across North America, Europe, and Asia. For more details, visit their website at www.ctscorp.com.

The recent appointment of Kimberly Banks MacKay to the Board of Directors of CTS Corporation (NYSE: CTS) marks a significant development for the company and its stakeholders. With over 30 years of experience in leading multinational corporations, particularly in the healthcare sector, MacKay’s arrival is poised to enhance CTS’s strategic direction, particularly in leveraging health-related technologies.

MacKay's expertise will likely contribute to CTS’s objectives of diversification and growth, especially given the company’s active engagement in end markets such as aerospace, industrial, medical, and transportation. Her position on both the Nominating, Governance, and Sustainability Committee, as well as the Technology and Transactions Committee, suggests that she will play a crucial role in shaping CTS’s innovation strategies and governance practices. This diversification could mitigate risks associated with reliance on any single market and enhance long-term stability.

Investors should pay close attention to how MacKay’s experience may drive future product developments and partnerships, particularly in the burgeoning healthcare technology sector. As health technology continues to expand, CTS’s focus on solutions that "Sense, Connect and Move" aligns well with current trends in smart devices and connected health solutions.

From a market standpoint, the timing of this appointment could suggest that CTS is positioning itself to capitalize on potential growth opportunities in a recovery phase post-pandemic, where investments in healthcare and technology integration are likely to increase. As such, maintaining or increasing positions in CTS could be considered favorable, particularly in light of a strong leadership team steering the company in strategic directions.

In summary, Kimberly Banks MacKay's extensive background and leadership capabilities provide CTS with an opportunity to enhance its market position and should be viewed as a positive catalyst by investors looking for growth in a diversified market landscape.